Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Sanofi-aventis 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Sanofi-aventis 4Q

Pharmaceutical sales were $9.0 billion (+3%) in 4Q09 and $37.0 billion (+4%) for FY09.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma


4Q Revenues: $10.2 billion (+4%)

4Q Earnings: $674.8 million (+18%)*

FY Revenues: $42.0 billion (+6%)

FY Earnings: $7.5 billion (+37%)*

Comments: Pharmaceutical sales were $9.0 billion (+3%) in 4Q09 and $37.0 billion(+4%) for FY09. Sales of Lantus were $1.1 billion in the quarter (+17%). Sales of Apidra were up 30% in the quarter to $53 million. Lovenox sales were up 8% to $1.1 billion. Taxotere sales were $763.6 million, up 4%. Sales of Eloxatin were down 81% to $96.0 million, due to generic competition. The company launched Multaq in the quarter with sales of $17.2 million. Vaccines sales were up 19%, with flu vaccine sales of $1.5 billion, including $630.4 million of A/H1N1 sales. Pentacel sales reached $488.5 million in the U.S. Exchange rates had an unfavorable effect of 5% in the quarter.

*Adjusted net income

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters